CVS Health will restore coverage of Eli Lilly's weight loss injection Zepbound on Oct. 1 and add coverage of its new obesity pill Foundayo on June 1, making both GLP-1 medications co-preferred options on its standard commercial formulary, affecting 25-30 million Americans and boosting Lilly's market position against Novo Nordisk.
Early signs from the launch of Novo Nordisk's Wegovy pill and Eli Lilly & Co.'s Foundayo are making investors rethink the opportunity for GLP-1 pills.
Early signs from the launch of Novo Nordisk's Wegovy pill and Eli Lilly & Co.'s Foundayo are making investors rethink the opportunity for GLP-1 pills.
Early signs from the launch of Novo Nordisk's Wegovy pill and Eli Lilly & Co.'s Foundayo are making investors rethink the opportunity for GLP-1 pills.
Eli Lilly's new GLP-1 weight loss pill Foundayo has attracted over 20,000 users in its first few weeks on the market, with more than 1,000 people starting the daily medication each day, CEO Dave Ricks said in a CNBC interview. The FDA approved Foundayo earlier this month, making it the second oral GLP-1 drug behind Novo Nordisk's Wegovy pill. More than 80% of Foundayo users are new to GLP-1s. Eli Lilly posted first-quarter earnings that beat expectations, with Mounjaro and Zepbound sales spiking 125% and 80% respectively.
